Abstract:Hepatocellular carcinoma (HCC) has a relatively higher incidence in many countries of Asia. Globally, HCC has a high fatality rate and short survival. Epirubicin, a doxorubicin analogue, may be administered alone or in combination with other agents to treat primary liver cancer and metastatic diseases. However, the toxic effects of epirubicin to normal tissues and cells have been one of the major obstacles to successful cancer chemotherapy. Here, we investigated the effects of epirubicin in combination with kappa-selenocarrageenan on mice with H22 implanted tumors and HepG-2 cell proliferation, immune organ index, morphology, cell cycle and related protein expressions in vivo and in vitro with sequential drug exposure. The inhibitory rate of tumor growth in vivo was calculated. Drug sensitivity was measured by MTT assay, and the King's principle was used to evaluate the interaction of drug combination. Morphological changes were observed by fluorescent microscopy. Cell cycle changes were analyzed by flow cytometry. Expression of cyclin A, Cdc25A and Cdk2 were detected by Western blotting. In vivo results demonstrated that the inhibitory rate of EPI combined with KSC was higher than that of KSC or EPI alone, and the Q value indicated an additive effect. In addition, KSC could significantly raise the thymus and spleen indices of mice with H22 implanted tumors. In the drug sensitivity assay in vitro, exposure to KSC and EPI simultaneously was more effective than exposure sequentially in HepG-2 cells, while exposure to KSC prior to EPI was more effective than exposure to EPI prior to KSC. Q values showed an additive effect in the simultaneous group and antagonistic effects in the sequential groups. Morphological analysis showed similar results to the drug sensitivity assay. Cell cycle analysis revealed that exposure to KSC or EPI alone arrested the cells in S phase in HepG-2 cells, exposure to KSC and EPI simultaneously caused accumulation in the S phase, an effect caused by either KSC or EPI. Expression of cyclin A, Cdc25A and Cdk2 protein was down-regulated following exposure to KSC and EPI alone or in combination, exposure to KSC and EPI simultaneously resulting in the lowest values. Taken together, our findings suggest that KSC in combination with EPI might have potential as a new therapeutic regimen against HCC.

Strategy to Enhance the Therapeutic Effect of Doxorubicin in Human Hepatocellular Carcinoma by Selenocystine, A Synergistic Agent That Regulates the Ros-Mediated Signaling

Enhancing Cisplatin Efficacy in Hepatocellular Carcinoma with Selenocystine: The Suppression of DNA Repair and Inhibition of Proliferation in Hepatoma Cells

Selenocystine Potentiates Cancer Cell Apoptosis Induced by 5-Fluorouracil by Triggering Reactive Oxygen Species-Mediated DNA Damage and Inactivation of the ERK Pathway

Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

Enhancement of Auranofin-Induced Apoptosis in MCF-7 Human Breast Cells by Selenocystine, a Synergistic Inhibitor of Thioredoxin Reductase

Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo

Synergistic Induction of Apoptosis by Methylseleninic Acid and Cisplatin, the Role of ROS-ERK/AKT-p53 Pathway

Synergistic Treatment of Cancer Stem Cells by Combinations of Antioncogenes and Doxorubicin

Selenium Sensitizes MCF-7 Breast Cancer Cells to Doxorubicin-Induced Apoptosis Through Modulation of Phospho-Akt and Its Downstream Substrates

Dual-function Nanosystem for Synergetic Cancer Chemo-/Radiotherapy Through ROS-mediated Signaling Pathways.

Synergy effects of copper ion in doxorubicin-based chelate prodrug for cancer chemo-chemodynamic combination therapy

Boost Therapy of Hepatocellular Carcinoma by Amplifying Vicious Cycle Between Mitochondrial Oxidative Stress and Endoplasmic Reticulum Stress Via Biodegradable Ultrasmall Nanoparticles and Old Drug

Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma

Synergistic Pro-Apoptotic Effect of a Cyclic RGD Peptide-Conjugated Magnetic Mesoporous Therapeutic Nanosystem on Hepatocellular Carcinoma HepG2 Cells

Sensitization of Cancer Cells to Radiation by Selenadiazole Derivatives by Regulation of ROS-mediated DNA Damage and ERK and AKT Pathways.

Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination

The Synergistic In Vitro And In Vivo Antitumor Effect Of Combination Therapy With Salinomycin And 5-Fluorouracil Against Hepatocellular Carcinoma

Targeted Delivery of Doxorubicin via CD147-Mediated ROS/pH Dual-Sensitive Nanomicelles for the Efficient Therapy of Hepatocellular Carcinoma

Doxorubicin and Curcumin Co-Delivery by Lipid Nanoparticles for Enhanced Treatment of Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice.

Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting nanotherapeutics

ATP-responsive copper(II)-doped ZIF-nanoparticles for synergistic cancer therapy: combining cuproptosis and chemo/chemodynamic therapy